These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 16428483)

  • 1. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.
    Ye B; Skates S; Mok SC; Horick NK; Rosenberg HF; Vitonis A; Edwards D; Sluss P; Han WK; Berkowitz RS; Cramer DW
    Clin Cancer Res; 2006 Jan; 12(2):432-41. PubMed ID: 16428483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer biomarkers in urine.
    Chambers AF; Vanderhyden BC
    Clin Cancer Res; 2006 Jan; 12(2):323-7. PubMed ID: 16428467
    [No Abstract]   [Full Text] [Related]  

  • 3. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
    Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C
    Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
    Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF
    Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].
    Zhao Q; Duan W; Wu YM; Qian XH; Deng XH
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):754-8. PubMed ID: 19173805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classifications of ovarian cancer tissues by proteomic patterns.
    Zhu Y; Wu R; Sangha N; Yoo C; Cho KR; Shedden KA; Katabuchi H; Lubman DM
    Proteomics; 2006 Nov; 6(21):5846-56. PubMed ID: 17068758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components.
    Taylor DD; Atay S; Metzinger DS; Gercel-Taylor C
    Gynecol Oncol; 2010 Feb; 116(2):213-21. PubMed ID: 19945743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma.
    Morita A; Miyagi E; Yasumitsu H; Kawasaki H; Hirano H; Hirahara F
    Proteomics; 2006 Nov; 6(21):5880-90. PubMed ID: 17022098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
    Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q
    Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
    Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
    Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of prognostic factors in common ovarian tumors of varying malignancy].
    Demeter A; Várkonyi T; Csapó Z; Szánthó A; Oláh J; Papp Z
    Magy Onkol; 2004; 48(3):259-65. PubMed ID: 15520877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
    Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
    Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins.
    Li B; An HJ; Kirmiz C; Lebrilla CB; Lam KS; Miyamoto S
    J Proteome Res; 2008 Sep; 7(9):3776-88. PubMed ID: 18642944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
    Jackson D; Craven RA; Hutson RC; Graze I; Lueth P; Tonge RP; Hartley JL; Nickson JA; Rayner SJ; Johnston C; Dieplinger B; Hubalek M; Wilkinson N; Perren TJ; Kehoe S; Hall GD; Daxenbichler G; Dieplinger H; Selby PJ; Banks RE
    Clin Cancer Res; 2007 Dec; 13(24):7370-9. PubMed ID: 18094419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
    Kong F; Nicole White C; Xiao X; Feng Y; Xu C; He D; Zhang Z; Yu Y
    Gynecol Oncol; 2006 Feb; 100(2):247-53. PubMed ID: 16229881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
    Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
    Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Identification of serum biomarkers for ovarian cancer using protein chips and time of flight mass spectrometry technology].
    Wang Q; Li L; Li DR; Zhang W; Wei X; Zhang JQ; Tang Y
    Zhonghua Fu Chan Ke Za Zhi; 2006 Aug; 41(8):544-8. PubMed ID: 17083841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
    Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
    Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.